Biocompatibles Hedging On Safety, Efficacy Goals For Drug-Coated Stents
This article was originally published in The Gray Sheet
Executive Summary
Biocompatibles is focusing on the safety of its dexamethasone-coated stent at the expense of efficacy in a bid to expedite regulatory approval, while stressing the reverse for its batimastat delivery program